Viking Therapeutics: Wall Street’s Bullish Bet on a GLP-1 Challenger

As U.S. markets operated on a shortened post-Thanksgiving schedule, research departments remained active, with Viking Therapeutics generating significant analyst enthusiasm. The biopharmaceutical company finds itself at the center of attention following Leerink Partners’ reaffirmation of their optimistic outlook, maintaining a $118 price target that suggests substantial growth potential from current trading levels near $36.27.

The pharmaceutical sector’s race to develop effective weight-loss treatments has created a market opportunity measured in trillions of dollars. Currently, industry giants Eli Lilly and Novo Nordisk maintain dominant positions with their GLP-1 agonist therapies. Viking Therapeutics aims to disrupt this established dynamic with its investigational compound VK2735, a dual-acting agent that simultaneously targets both GLP-1 and Read more...